Clarient, Inc. Launches Gene Expression Test for Prostate Cancer

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Clarient, Inc. (Nasdaq: CLRT - News), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists, and the pharmaceutical industry, today announced the commercial launch of its new gene expression test for prostate cancer. This new test will be available through Clarient’s PATHSiTETM virtual reporting tool and accessible to the company’s entire pathology network
Clarient’s new test is based on a unique and patent protected combination of four genes that have been shown to accurately identify the presence of Grade 3 or higher (clinically significant cancer) prostate cancer cells in prostate tissue. The association of these four genes with prostate cancer was discovered by Health Discovery Corporation (OTCBB: HDVY - News) using their patented SVM and SVM-RFE pattern recognition technology.

Full article >> http://www.devicespace.com/news_story.aspx?NewsEntityId=122689